Mayr, C.; Kiesslich, T.; Erber, S.; Bekric, D.; Dobias, H.; Beyreis, M.; Ritter, M.; Jäger, T.; Neumayer, B.; Winkelmann, P.;
et al. HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers 2021, 13, 3862.
https://doi.org/10.3390/cancers13153862
AMA Style
Mayr C, Kiesslich T, Erber S, Bekric D, Dobias H, Beyreis M, Ritter M, Jäger T, Neumayer B, Winkelmann P,
et al. HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers. 2021; 13(15):3862.
https://doi.org/10.3390/cancers13153862
Chicago/Turabian Style
Mayr, Christian, Tobias Kiesslich, Sara Erber, Dino Bekric, Heidemarie Dobias, Marlena Beyreis, Markus Ritter, Tarkan Jäger, Bettina Neumayer, Paul Winkelmann,
and et al. 2021. "HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer" Cancers 13, no. 15: 3862.
https://doi.org/10.3390/cancers13153862
APA Style
Mayr, C., Kiesslich, T., Erber, S., Bekric, D., Dobias, H., Beyreis, M., Ritter, M., Jäger, T., Neumayer, B., Winkelmann, P., Klieser, E., & Neureiter, D.
(2021). HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers, 13(15), 3862.
https://doi.org/10.3390/cancers13153862
